Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2)

Gaetano Bertino,1 Rosalia Ragusa,2 Liberato Simone Corsaro,3 Evelise Frazzetto,1 Vincenzo Messina,4 Lucio Inguscio,5 Carlo Lai,5 Marilena Maglia,6 Andrea Nunnari,7 Pasquale Caponnetto6

1Hepatology Unit, Policlinic “G. Rodolico”, Department of Clinical and Experimental Medicine, University of Catania; 2Health Technology Assessment Committee, University Hospital “G. Rodolico”, Catania; 3Biologist, Master of Science in Clinical Trial Governance, University of Catania; 4Infectious Disease Unit, Azienda Ospedaliera “S. Anna e S. Sebastiano” of Caserta; 5Department of Dynamic and Clinical Psychology, University of Rome La Sapienza, Rome; 6Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Department of Clinical and Experimental Medicine, University of Catania; 7School of Medicine, Course of Rehabilitation Science for Health Professions, Università di Catania, Italy

Abstract

HCV (Hepatitis C Virus) decreases Health-Related Quality of Life with detriments to physical, mental and social health domains. Interferon and Ribavirin treatment is associated with depression and anxiety that further impairs HRQoL (Health-Related Quality of Life). IFN-free (interferon-free) regimes (Direct Acting Antivirals, DAAs) are safe and highly effective drugs, with improvement also of HRQoL and related Psychological Well-Being. Our aim is to describe how the latest generation IFN-free treatment can change quality of life and related Psychological Well-Being

Introduction

Starting on 2011 the landscape of HCV (hepatitis C virus) therapy has experienced a real revolution (Bansal, Singal, McGuire & Anand, 2015; Bertino et al., 2016). The improvement of molecular biology techniques has allowed us to perfectly understand viral infection and replication, so IFN-based (interferon-based) treatments were definitively dismissed to develop and introduce in clinical practice IFN-free (interferon-free) treatments thanks to Direct-acting Antiviral Agents (DAAs) [Bertino et al., 2016; American Association for the Study of Liver Disease (AASLD), 2017].

The aim of therapy is eradication of HCV that slows the pro-
gression of liver disease and improves the survival, by reducing the risk of decompensation and liver cancer (AASLD, 2017). The end-point of therapy is undetectable HCV-RNA in serum or plasma by a sensitive assay (lower limit of detection ≤15 IU/mL) 12 weeks (SVR12, Sustained Virological Response 12) or 24 weeks (SVR24, Sustained Virological Response 24) after the End of Treatment (EOT) (AASLD, 2017).

Sustained Virological Response (SVR) indicates the eradication of HCV and has many hepatic benefits: improves liver necroinflammation, fibrosis, reduces also risk of HCC (Hepatitis C Cancer), hepatic decompensation and liver-related mortality (Cabibbo et al., 2019; Wei & Huang, 2019).

DAAs are safe and effective drugs, with SVR rates above 97-98% (according to HCV genotype and comorbidity) (Bertino et al., 2018; Cabibbo et al., 2017; Calvaruso et al., 2018; Calvaruso et al., 2019; Corsaro and Ragusa, 2018.).

DAAs therapy has also a shorter duration than IFN-based therapy, only 8 or 12 weeks, according to HCV genotypes, staging of liver fibrosis (F1-F4), comorbidity (drug-drug interactions), renal function [European Association for the Study of the Liver (EASL), 2018].

Furthermore, HCV eradication has many extrahepatic benefits: improves extrahepatic manifestations (e.g. cryoglobulinemic syndromes, lymphoproliferative B-cell syndromes) and non-specific symptoms such as fatigue, nausea, abdominal pain, weight loss (Kuna, Jakab, Smolic, Wu and Smolic, 2019; Polo and Laufer, 2017).

Patients with chronic HCV infection are more likely to develop insulin resistance and diabetes, cognitive dysfunction and depression (Kuna et al., 2019). A health-related definition of Quality of Life (HRQoL) is developed taking into account health-related aspects of QoL (Quality of Life). The WHO (World Health Organization) (2014) defines HRQoL as “those aspects of self-perceived well-being that are related to or influenced by the presence of disease or treatment”. This concept is sometimes expressed in a narrower sense, in which HRQoL “is used to identify the subset of the important or the most common ways in which health or health care affects well-being” (Ebrahim, 1995). Another aspect to consider for HRQoL is the value of health. HRQoL can be tied to “values as signed for different states of integrity” (Peasgood, Brazier, Mukuria and Rowen, 2014). Other research was based on health questionnaires in which a significant improvement in quality of life scores was closely linked to a sustained viral response (Bernstein, Kleinman, Barker, Revicki and Green, 2002; Gold et al., 1996), especially in those patients with chronic hepatitis.

The change in HRQoL in HCV-infected patients who are treated with IFN appears to be due to the IFN itself which being pro-inflammatory cytokine inducing neuropsychiatric symptoms. Therefore, a percentage of subjects between 12% and 41% affected in inflammatory cytokine inducing neuropsychiatric symptoms, even if these events did not belong to the patient’s natural history (McHutchison et al., 2002). This percentage increases, involving from 17% to 58% of patients, with symptoms mainly related to depression, if there had been a neuropsychiatric syndrome in the patient’s history (McHutchison et al., 2002) as consequence IFN-α could be associated with psychiatric adverse effects which can also worsen existing psychiatric conditions (Horsmans, 2006; Quelhas and Lopes, 2009). In addition, depression or related symptoms develop more frequently during IFN-α therapy, with over 25% of patients receiving IFN-α therapy showing treatment-induced depression (Keefe, 2007).

Works aimed at assessing the quality of life, conducted using the health questionnaire, show that interferon regimes impair physical and mental health (Madorfer et al., 2014). In contrast to IFN-based regimes, highly effective and well-tolerated IFN-free regimes improve HRQoL already during treatment (Scheiner et al., 2016). The arrival of direct-acting antivirals, which boast relatively high efficacy, low toxicity and high prices, requires the use of disease-sensitive HRQoL measures so that action can be taken promptly in the choice of treatment (Bethea, Chen, Hur, Chung and Chhatwal, 2018; Corsaro and Ragusa, 2018). Altogether, a successful treatment generates a containment of liver-related morbidity and an improvement in health-related quality of life (Ragusa et al., 2018; Younossi and Henry, 2015).

This work focused on the impact that virus-related factors have on HRQoL and what type of impact direct antivirals, used on patients with chronic hepatitis C/cirrhosis, have on their HRQoL and Psychological Well-Being.

Methods

Study population and medical treatment

During a period of 12 months (from February 2018 to February 2019) adult patients with Chronic HCV infection, 7 cirrhotic and 163 non-cirrhotic, were enrolled for treatment with DAAs in two Italian Hospitals: i) Hepatology Unit, Azienda Ospedaliero Universitaria “Policlinico - Vittorio Emanuele” of Catania, and ii) Infectious Disease Unit, Azienda Ospedaliero “S. Anna e S. Sebastiano” of Caserta.

Before treatment, each patient had undergone to staging of liver disease (blood chemistry tests, Ultrasonography, Transient Elastography, and esophagagogastroduodenoscopy) and to a virological evaluation (HCV genotype and serum viral load, HBV and HIV co-infection).

The diagnosis of cirrhosis included at least one of the following criteria: previous liver biopsy, a liver stiffness > 12 kPa at Transient Elastography, or esophageal and/or gastric varices. Functional class of Cirrhosis was attributed with Child-Pugh score, all patients (7) with cirrhosis were in a Child-Pugh score A.

HCV-RNA levels were determined with real-time PCR-based assays (Roche TaqMan; LLOD 15 IU/mL) and were evaluated: before treatment (baseline); at weeks 8 or 12 of therapy (end of therapy, EOT);12 weeks after EOT (Sustained Virological Response 12 weeks, SVR 12). The Hepatitis Quality of Life Questionnaire (HQLQv2TM) was selected to assess Quality of life and Psychological Well-being and administered to all patients before treatment (baseline, T0) and 12 weeks after the end of therapy (SVR12, T1).

Measures

The Hepatitis Quality of Life Questionnaire (HQLQ), version 2 (HQLQv2), was used to assess both generic and disease-specific elements of Quality of Life and Psychological Well-Being (Bayliss et al., 1998). The HQLQ includes the Short Form-36 version 2 items (which can be used to assess generic aspects of health status) and four hepatitis-specific health domain scores: health distress (HD, 4 items), positive well-being (PWb, 4 items), hepatitis-specific limitations (HLIM, 3 items) and hepatitis-specific health distress (HHD, 4 items). The original authors designed the SF-36 to measure health at the individual level in clinical practice and research, and at the population level for health policy evaluations, and general population surveys (Ware Jr. & Sherbourne, 1992). It
has been used in thousands of research studies (Lims and Carvalho, 2016) and was originally designed as a generic health measure but has also been applied to specific disease populations.

The SF-36 version 2 (SF-36v2) questionnaire (Ware et al., 1995) is a self-administered questionnaire comprised of a total of 36 items with two (physical and mental) components. The Physical Component Summary (PCS) and the Mental Component Summary (MCS) include four domains respectively. The physical health measure includes four scales of physical functioning (PF, 10 items), role-physical (RP, 4 items), bodily pain (BP, 2 items), and general health (GH, 6 items). The mental health measure is composed of vitality (VT, 4 items), social functioning (SF, 2 items), role-emotional (RE, 3 items), and mental health (MH, 5 items).

Optum Life Sciences licensed the usage of the questionnaire survey. By using the standard IQOLA translation methodology (Bullinger et al., 1998), translation from English to Italian was performed by Pasquale Caponnetto, Evelise Frazzetto and Marilena Maglia, and approved by Optum (Office of Grant and Scholarly Research - Johnston, RI, USA).

Internal consistency reliability of the SF-36v2 and HQLQv2 was determined from Cronbach’s alpha (α) of each of the 8 domains and item-scale correlation (corrected for overlap). Spearman’s correlation was used to determine the correlation between items and scales (Alhaji et al., 2018).

Each raw domain score can be converted into a 0–100 scale, with a higher score indicating a higher health status (i.e., a score of 0 indicates the least favorable health status; a score of 100, the most favorable health status). To obtain this type of score, the answers to the HQLQv2 questionnaire have been converted into a numerical likert scale (for example, 0: “always”, 1: “often”, 2: “from time to time”, 3: “rarely”, 4: “never”). That data was introduced in an Excel file (.csv) which has been shared with Optum Life Sciences® [QualityMetric (Canada) Inc.] via Accellion (secure file sharing platform).

QualityMetric Health Outcome Scoring Software (QualityMetric, Lincoln, RI) performed final score of each domain and scale that was shared with us via Accellion.

The file that QualityMetric shared with us contains another scale called NBS (Norm Based Score). These are the SF-36v2 scale scores normed to the United States population to have a mean of 50 and standard deviation of 10.

For all summary and domain scores, higher scores indicate greater quality of life. For generic summary and domain scores, differences between groups of 3 and 5 points, respectively, represent clinically meaningful differences (Maruish, 2011).

Statistical methods

The Statistical Package for the Social Sciences V 25.0 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.) was used for the data analysis. Descriptive statistics were computed to summarize data. Individual variables were examined by percentages, means, and standard deviations (SDs). Differences between pre and post treatment results were assessed with analysis of mean difference between posttest score and pretest score (d), standard deviation of the difference between posttest score and pretest score (SD) and analysis of standardized response mean (SRM). This index was calculated as d/SD (Zhou et al., 2013). We explained the SRM index also with a paired-samples t-test.

To measure the reliability of psychometric tests we use Cronbach’s alpha, also called alpha (α). Internal consistency reliability was measured by Cronbach’s α, with the value greater than 0.70 representing acceptable reliability. Test-retest reliability was measured by Intra-Class Correlation (ICC) between the 12-weeks test-retest results. ICC < 0.40 is considered poor to fair agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80 good agreement, and >0.80 excellent agreement (Bartko, 1966). We also calculated Spearman’s correlation coefficients for all scales.

The calculation will refer to all scale dimensions: SF-36v2 (pre and post) SF-36v2NBS (pre and post), SF-36v2 Component summaries (pre-post), and HQLQv2 (pre-post).

A multivariate analysis of the data was carried out to determine the possible significance of the sex factor in the evaluation of the results. In particular, the “Trace of Pillai”, the “Lambda of Wilks”, the “Trace of Hotelling”. Furthermore, the “Greater Roy’s Root” and the “Mauchly’s Spherical Test” were used.

Results

Characteristics of participants

A total of 72 patients completed the HQLQv2 before the initiation and at the end of their DAA treatments at two Italian hospital centers.

All patients complete the treatment, without serious adverse events, drop out or withdraw therapy or death (liver- and no liver-related) and the rate of Sustained Virological Response was 100%.

The demographic and medical characteristics revealed that the mean age of the sample (n=72) was 62.28 ± [Standard Deviation (SD) 13.53]. The sample contained a different percentage of males (61%) and females (39%). The majority of participants (90.3%) showed chronic HCV related hepatitis (CHC) with 9.7% affected by liver cirrhosis.

The individuals considered by our study with a genotype different from genotype 1, represent 29.2% of the population. They were distributed as follows: 15.3% with genotype 2, 11.1% with genotype 3 and 2.8% with genotype 4. 43.1% of participants presented medical comorbidities at risk of progression of liver damage [chronic non-viral liver diseases, diabetes mellitus in drug treatment, obesity (body mass index ≥30 kg/m²), hemoglobinopathies and congenital coagulopathies]. Finally, 25% of patients had hepatic steatosis, of which 33.3% had mild hepatic steatosis.

Scoring analysis

For each item of the questionnaire, the results in terms of improvement, deterioration and stagnation (or status quo) comparing the score provided to us by Optum® between T0 and T1, showed that for most of the domains there was a score increasing after DAA treatments (“improvement” or “improv.”. Figure 1) suggesting an overall improvement Quality of Life and Psychological Well-Being.

It should be noted that most of those who had the same constant score between T0 and T1 had a high score (T0) and maintained it even after therapy (T1) (“stable”). This suggests that therapy did not deteriorate the quality of life Quality of Life and Psychological Well-Being of this group of patients or significantly influence those who already had a good parameter.

Statistical analysis

The average scores for most of the individual domains at T1 are higher than those at time T0. This reflects the scoring analysis seen in the Table 1.

Comparing with the US population, given that there is an
Table 1. The responsiveness of the SF-36v2 and the HQLQ: scores (mean ± SD), ^d (average mean difference), Sd (standard deviation of difference) and standardized response mean (SRM) stratified on improvement, status quo, or deterioration in health status.

| SF-36v2 | Measurement of time | Pretest | Posttest | ^d     | Sd     | SRM    | %      |
|---------|---------------------|---------|----------|--------|--------|--------|--------|
| Health status: improvement | | | | | | | |
| Physical functioning (PF) (n=26) | 36,71±11,74 | 52,97±7,32 | 7,31 | 16,26** | 11,33 | 1,43 | 44 |
| Role-physical (RP) (n=30) | 33,87±9,18 | 48,24±8,12 | 8,08 | 14,37** | 9,73 | 1,47 | 43 |
| Bodily pain (BP) (n=35) | 40,26±9,01 | 54,27±8,13 | 8,25 | 14,01** | 10,04 | 1,39 | 46 |
| General health (GH) (n=42) | 42,06±9,64 | 53,45±6,47 | 7,32 | 10,75** | 9,51 | 1,13 | 56 |
| Vitality (VT) (n=37) | 43,92±9,83 | 56,45±8,71 | 8,79 | 13,34** | 9,93 | 1,34 | 62 |
| Social functioning (SF) (n=32) | 38,22±8,67 | 51,20±7,39 | 5,39 | 13,16** | 7,5 | 1,75 | 62 |
| Role-emotional (RE) (n=34) | 29,33±8,76 | 45,92±9,14 | 9,78 | 17,1** | 10 | 1,7 | 51 |
| Mental health (MH) (n=37) | 38,89±9,14 | 51,36±10,77 | 7,9 | 13,54** | 10,22 | 1,32 | 51 |
| Health status: deterioration | | | | | | | |
| Physical functioning (PF) (n=21) | 52,34±5,24 | 40,68±10,24 | -6,73 | -11,66** | 7,93 | -1,47 | 30 |
| Role-physical (RP) (n=22) | 53,15±4,97 | 39,97±7,82 | -9,88 | -13,18** | 6,39 | -2,06 | 30 |
| Bodily pain (BP) (n=17) | 51,89±10,38 | 41,38±7,75 | -10,51 | -13,58** | 12,62 | -1,07 | 27 |
| General health (GH) (n=17) | 49,74±8,00 | 41,29±6,91 | -8,25 | -8,44** | 5,57 | -1,51 | 26 |
| Vitality (VT) (n=17) | 58,36±6,34 | 47,70±7,71 | -10,66 | -13,18** | 7,91 | -1,39 | 29 |
| Social functioning (SF) (n=21) | 52,56±7,34 | 39,91±7,30 | -12,55 | -12,17** | 8,47 | -1,43 | 30 |
| Role-emotional (RE) (n=24) | 52,25±4,95 | 38,61±9,71 | -7,04 | -14,21** | 9,23 | -1,53 | 32 |
| Mental health (MH) (n=22) | 50,86±6,14 | 41,95±6,92 | -8,92 | -9,51** | 7,15 | -1,32 | 34 |
| Health status: status quo | | | | | | | |
| Physical functioning (PF) (n=12) | 59,98±4,91 | 54,98±4,91 | 0 | 36,04** | 20 |
| Role-physical (RP) (n=10) | 56,26±1,89 | 56,26±1,89 | 0 | 36,04** | 22 |
| Bodily pain (BP) (n=20) | 56,59±8,88 | 56,09±9,01 | 0 | 36,04** | 15 |
| General health (GH) (n=7) | 48,19±11,94 | 48,19±11,94 | 0 | 36,04** | 16 |
| Vitality (VT) (n=6) | 52,69±2,62 | 52,69±2,62 | 0 | 36,04** | 8 |
| Social functioning (SF) (n=12) | 50,5±7,52 | 50,5±7,52 | 0 | 36,04** | 22 |
| Role-emotional (RE) (n=9) | 48,43±8,6 | 48,43±8,6 | 0 | 36,04** | 24 |
| Mental health (MH) (n=4) | 46,16±10,69 | 46,16±10,69 | 0 | 36,04** | 6 |
| HQLQ inventory | Health status: improvement | | | | | | |
| Health Distress (HD) (n=38) | 41,11±27,63 | 76,48±20,92 | 9,801 | 35,36** | 22,24 | 1,58 | 59 |
| Positive Well-Being (PWB) (n=39) | 40,38±21,59 | 65,86±17,89 | 8,02 | 23,48** | 19,83 | 1,28 | 60 |
| Hepatitis-specific Limitations (HLIM) (n=32) | 46,15±27,07 | 83,15±22,41 | 9,42 | 37** | 22,21 | 1,66 | 48 |
| Hepatitis-specific Health Distress (HHD) (n=43) | 42,28±28,35 | 77,07±20,14 | 10,88 | 35,46** | 23,05 | 1,53 | 60 |
| Health Distress (HD) (n=38) | 41,11±27,63 | 76,48±20,92 | 9,801 | 35,36** | 22,24 | 1,58 | 59 |
| HQLQ inventory | Health status: deterioration | | | | | | |
| Health Distress (HD) (n=21) | 77,38±12,72 | 48,51±16,75 | -28,86** | 15,99 | -1,8 | 32 |
| Positive Well-Being (PWB) (n=18) | 65,27±19,20 | 45,83±16,74 | -5,74 | -31,25** | 14,69 | -2,12 | 27 |
| Hepatitis-specific Limitations (HLIM) (n=19) | 85,84±18,16 | 56,05±22,85 | -29,78** | 18,07 | -1,64 | 28 |
| Hepatitis-specific Health Distress (HHD) (n=25) | 73,31±27,01 | 49,51±30,81 | -34,66** | 22,66 | -1,48 | 36 |
| Health Distress (HD) (n=6) | 72,91±20,41 | 72,91±20,41 | 0 | 8,01 | 9 |
| Positive Well-Being (PWB) (n=8) | 60,93±21,32 | 60,93±21,32 | 0 | 8,01 | 13 |
| Hepatitis-specific Limitations (HLIM) (n=16) | 88,5±29,19 | 88,5±29,19 | 0 | 8,01 | 23 |
| Hepatitis-specific Health Distress (HHD) (n=4) | 57,81±20 | 57,81±20 | 0 | 8,01 | 4 |

SD: standard deviation. ^d: mean difference between posttest score and pretest score. Sd: standard deviation of the difference between posttest score and pretest score. SRM: standardized response mean was calculated as Sd. The SRM ≥ 1.00 was in bold. Paired-samples t-test: * P<0.05. ** P<0.01.
increase in the average of the results for each single variable in the pre-post therapy comparison, our results are similar with the US data HCV population. In fact, it presents average values very close to 50 and with a standard deviation around 10 both before and after therapy. This confirms two aspects: the therapy does not affect but improves the general quality of the patient’s life and their associated Psychological Well-Being, and that our sample is potentially comparable to the population treated with direct antivirals of the United States.

We calculated the responsiveness of the SF-36v2 and the HQLQ: scores (mean ± SD) and Standardized Response Mean (SRM) stratified on improvement, status quo, or deterioration in health status.

Table 1 summarizes the performed statistical test. All domains have statistical significance (p<0.001) for “improvement” and “deterioration” of health condition (not for “status quo or stable” health condition).

In the SF-36v2 domains, the 53% of Ss (Scores) show an improvement in a significant way, the 30% show a deterioration of health condition and the 17% of Ss have a stable health condition.

In the HQLQv2, the responsiveness shows a same trend: improvement (57%), deterioration (31%), stable (12%).

To measure the reliability of psychometric tests we use the “Cronbach alpha”, also called “alpha”. The reliability of the HQLQ INVENTORY was evaluated with regard to the homogeneity of the items, that is, the internal consistency (estimated by the Cronbach’s alpha coefficient) and Intraclass Correlation Coefficient (ICC).

Regarding internal consistency by the Cronbach’s alpha coefficient, an alpha > 0.70 was considered satisfactory. For the stability of the measure, the ICC was used, considering evidence of stability ICC > 0.70.

Values estimated by the Cronbach’s alpha were satisfactory for the Physical Components, except for the General Health sub-scale. In the Mental Component, only the Role Emotional Scale has an alpha = 0.94 and a ICC index= 0.89. In Vitality, General Health and Social Functioning Scales, alpha observed was not reliable and a total-item score correlation was not observed (Table 2).

The last four pre-therapy domains examined (HD, PWB, HLIM, HHD) included those related to the liver pathology examined. Here Cronbach’s alpha was equal to: 0.9 (HD), 0.86 (PWB), 0.95 (HLIM), 0.94 (HHD) so the scores were reliable. The alpha for the same four post-therapy domains was equal to 0.9 (HD), 0.85 (PWB), 0.94 (HLIM), 0.93 (HHD) so that reliability was reached also in this case. For this last group the reliability was more than good for the pre-therapy results (being higher than 0.8) while it is more than fair almost good for the results obtained in the post-therapy. Table 3 shows Spearman’s correlation coefficients calculated as other test-retest index (Spearman’s correlation coefficients tot. 0.538).

The ANOVA (Analysis of Variance) for all scales taken into consideration, namely SF-36v2 (pre and post) SF-36v2NBS (pre and post), SF-36v2 Component summaries (pre and post) HQLQv2 (pre and post), can always be superimposed with the average of the various variables and domains belonging to each scale. Further confirming the reliability of the results obtained. Finally, multivariate tests were used to verify if the gender factor could have a role in the perception of improvement or deterioration in the quality of life and associated psychological well-being. This aspect is potentially significant, as it is well known that women perceive pain differently than men (Belfer, 2017; Pieretti et al., 2016).

For these reasons, the “Trace of Pillai”, the “Lambda of Wilks”, the “Trace of Hotelling”, the “Root of Greater Roy” and

---

**Figure 1. Score analysis: improve involves the greatest number of patients in most of the domains.**

Legend: PF: Physical Functioning; RP: Role Physical; BP: Bodily Pain; GH: General Health; VT: Vitality Scale; SF: Social Functioning; RE: Role Emotional; MH: Mental Health; PCS: Physical Component Summary; MCS: Mental Component Summary; HD: Health Distress; PWB: Positive Wellbeing; HLIM: Hepatitis-specific Limitation; HHD: Hepatitis-specific Health Distress.
the “Test of Sphericity of Mauchly” were used. These statistical tests were performed on the scores for the first and second administration of the “HQLQv2” questionnaire taking into consideration the gender. All statistical tests showed that the gender factor, relative to our sample, is not significant in the perception of an improvement or deterioration in post-administration quality of life and associated psychological well-being of DAAs.

### Discussion and conclusions

HCV infection reduces the quality of life and psychological well-being of chronically affected patients. Among the various symptoms, in addition to the physical ones, there are depression, fatigue, anxiety and mental deterioration, and psychological and psychopathological factors such as mood, emotion, affective state and anxiety in chronic physical conditions can have an important

### Table 2. Item-total correlation, Cronbach’s alpha coefficient and valid case of HQLQ inventory.

| SF36v2 Scale                  | Item (n) correlation | Item-total Alpha | Cronbach’s Alpha (if item deleted) | Cronbach’s Case | Valid | ICC | IC95%† |
|-------------------------------|----------------------|------------------|-----------------------------------|-----------------|-------|-----|--------|
| Physical Functioning (PCS)    |                      |                  |                                   |                 |       |     |        |
| Item 1                        | 0.689                | 0.953            | 0.954                             | 63              | 0.7   | 0.6-0.75 |
| Item 2                        | 0.843                |                  | 0.947                             |                 |       |     |        |
| Item 3                        | 0.828                |                  | 0.947                             |                 |       |     |        |
| Item 4                        | 0.817                |                  | 0.948                             |                 |       |     |        |
| Item 5                        | 0.884                |                  | 0.946                             |                 |       |     |        |
| Item 6                        | 0.808                |                  | 0.949                             |                 |       |     |        |
| Item 7                        | 0.814                |                  | 0.948                             |                 |       |     |        |
| Item 8                        | 0.850                |                  | 0.947                             |                 |       |     |        |
| Item 9                        | 0.768                |                  | 0.950                             |                 |       |     |        |
| Item 10                       | 0.757                |                  | 0.951                             |                 |       |     |        |
| Role-Physical (PCS)           |                      |                  |                                   |                 |       |     |        |
| Item 11                       | 0.912                | 0.950            | 0.939                             | 66              | 0.83  | 0.77-0.88 |
| Item 12                       | 0.878                |                  | 0.941                             |                 |       |     |        |
| Item 13                       | 0.858                |                  | 0.933                             |                 |       |     |        |
| Item 14                       | 0.885                |                  | 0.939                             |                 |       |     |        |
| Bodily Pain (PCS)             |                      |                  |                                   |                 |       |     |        |
| Item 15                       | 0.816                | 0.889            | 0.948                             | 71              | 0.81  | 0.72-0.88 |
| Item 16                       | 0.816                |                  | 0.950                             |                 |       |     |        |
| General Health (PCS) from item 17 to 22 | 6 | Not reliable | | | |
| Vitality (MCS) from item 23 to 26 | 4 | Not reliable | | | |
| Social Functioning (MCS) item 27-28 | 2 | Not reliable | | | |
| Role-Emotional (MCS)          |                      |                  |                                   |                 |       |     |        |
| Item 29                       | 0.924                | 0.944            | 0.895                             | 69              | 0.89  | 0.78-0.89 |
| Item 30                       | 0.938                |                  | 0.921                             |                 |       |     |        |
| Item 31                       | 0.888                |                  | 0.937                             |                 |       |     |        |
| Mental Health (MCS) from item 32 to 36 | 5 | Not reliable | | | |
| HQLQv2 Scale                  |                      |                  |                                   |                 |       |     |        |
| Health distress               |                      |                  |                                   |                 |       |     |        |
| Item 1                        | 0.782                | 0.9               | 0.885                             | 70.000          | 0.71  | 0.61-0.79 |
| Item 2                        | 0.835                |                  | 0.865                             |                 |       |     |        |
| Item 3                        | 0.763                |                  | 0.890                             |                 |       |     |        |
| Item 4                        | 0.796                |                  | 0.881                             |                 |       |     |        |
| Positive well-being           |                      |                  |                                   |                 |       |     |        |
| Item 5                        | 0.672                | 0.86              | 0.850                             | 69.000          | 0.7   | 0.61-0.72 |
| Item 6                        | 0.764                |                  | 0.814                             |                 |       |     |        |
| Item 7                        | 0.817                |                  | 0.794                             |                 |       |     |        |
| Item 8                        | 0.650                |                  | 0.867                             |                 |       |     |        |
| Hepatitis specific limitations |                      |                  |                                   |                 |       |     |        |
| Item 9                        | 0.860                | 0.95              | 0.962                             | 70.000          | 0.87  | 0.81-0.93 |
| Item 10                       | 0.944                |                  | 0.898                             |                 |       |     |        |
| Item 11                       | 0.901                |                  | 0.951                             |                 |       |     |        |
| Hepatitis-specific health distress | 5 | Not reliable | | | |
role on medical symptom burden (Caponetto, Lai, Maglia & Cosci, 2020; Katon, Lin & Kroenke 2007) and on health behaviors such as adherence (Di Matteo, Lepper & Croghan, 2000) so a pharmacotherapy that doesn’t alter the psychological balance is of great importance (Caponetto et al., 2020).

Through the HQLQv2 scores analysis and the statistical results, it was shown that, overall, the participants’ general state of health improved at the end of the drug therapy (carried out with three antiviral drugs combinations: Sofosbuvir – Velpatasvir; Glecaprevir – Pibrentasvir and Elbasvir – Grazoprevir) and suggested that the participants’ quality of life examined is projected towards improving the overall functioning at the social, work, physical, psychological and other areas examined by the HQLQv2 questionnaire.

These statistical results, together with the proximity of the scores obtained with respect to the average US population, confirm that our sample, although not large, is representative.

Finally, although the literature demonstrates a different perception of physical pain related to gender, this does not emerge in this study. Our patients, in fact, did not show a particular difference, linked to gender, in providing their perception, for each of the variables taken into consideration by the questionnaire.

Two important limitations of this study are the not large sample size and the large number of variables in relation to the number of participants and the many different treatment schedules.

In conclusion, results support the observation that patients exposed to DAAs generally maintain the pre-treatment baseline score three months after completing antiviral therapy, or even exceed it. This once again expresses the safe profile of this intevention, as the authors demonstrate, to improve the overall functioning at the social, work, physical, psychological and other areas examined by the HQLQv2 questionnaire.

Table 3. Cronbach’s coefficient and Spearman’s correlation coefficients. Internal consistency and 12-weeks retest reliability of HQLQ inventory.

| Cronbach’s α coefficient | Retest reliability (after 12 weeks) |
|--------------------------|-------------------------------------|
| Physical functioning (PF) | 0.95 | 0.683** |
| Role-physical (RP)       | 0.95 | 0.479** |
| Bodily pain (BP)         | 0.88 | 0.51** |
| General health (GH)      | Not reliable | Ns |
| Vitality (VT)            | Not reliable | Ns |
| Social functioning (SF)  | Not reliable | Ns |
| Role-emotional (RE)      | 0.94 | 0.454** |
| Mental health (MH)       | Not reliable | Ns |
| Health distress (HD)     | 0.9 | 0.548** |
| Positive well-being (PWB) | 0.86 | 0.537* |
| Hepatitis-specific limitations (HILIM) | 0.95 | 0.483** |
| Hepatitis-specific health distress (HHD) | 0.94 | 0.619** |

References

Alhaji, M. M., Johan, N. H., Sharbini, S., Abdul Hamid, M. R., Khalil, M., Tan, J., Naing, L., & Tuah, N. (2018). Psychometric Evaluation of the Brunei-Malay SF-36 version 2 Health Survey, Asian Pacific Journal of Cancer Prevention, 19(7), 1859–1865.

American Association for the Study of Liver Disease (AASLD). (2017). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62, 932–954.

Bansal, S., Singh, A. K., McGuire, B. M., & Anand, B. S. (2015). Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World Journal of Hepatology, 7(5), 806–813.

Bartko, J. J. (1966). The intraclass correlation coefficient as a measure of reliability. Psychological Reports, 19(1), 3–11.

Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E., Jr (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7(1), 39–55.

Belfer, I. (2017). Pain in women. Agri, 29(2), 51–54.

Bernstein, D., Kleinman, L., Barker, C.M., Revicki, D.A. & Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 35, 704–708.

Bertino, G., Ardiri, A., Protti, M., Rigano, G., Frazzetto, E., Demma, S., Ruggeri, M. I., Scuderi, L., Malaguarnera, G., Bertino, N., Rapisarda, V., Di Carlo, I., Toro, A., Salomone, F., Malaguarnera, M., Bertino, E., & Malaguarnera, M. (2016). Chronic hepatitis C: This and the new era of treatment. World Journal of Hepatology, 8(2), 92–106.

Bertino, G., Malaguarnera, G., Frazzetto, E., Sciuto, A., Inserna, G., Zanghi, G. N., & Malaguarnera, M. (2018). Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. World Journal of Hepatology, 10(6), 448–451.

Bethea, E.D., Chen, Q., Hur, C., Chung, R.T. and Chhatwal, J. (2018). Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology, 67(3), 837-846.

Bullinger, M., Alonso, J., Apolone, G., Leplège, A., Sullivan, M., Wood-Dauphinee, S., Gandek, B., Wagner, A., Aaronson, N., Bech, P., Fukushima, S., Kaasa, S., & Ware, J. E., Jr (1998). Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. Journal of Clinical Epidemiology, 51(11), 913–923.

Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M. R., Madonia, S., Rossi, M., Magro, B., Rini, F., Distefano, M., Larocca, L., Prestileo, T., Malizia, G., Bertino, G., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Di Rosolini, M. A., Alaimo, G., Averna, A., Cartabellotta, F., Alessi, N., Guastella, S., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Trevisan, Craxi, A., Di Marco, V., Cammà, C., Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group (2019). Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Journal of Hepatology, 71(2), 265–273.

Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, I., Cannavò, M. R., Madonia, S., Distefano, M., Larocca, L., Prestileo, T., Tinè, F., Bertino, G., Giannitrapani, L., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Cartabellotta, F., Alessi, N., Barbàra, M.,
Russello, M., Scifo, G. Squadrito, G., Raimondo, G., Craxi, A., Di Marco, V., Cammà, C., Rete Sicilia Selezione Terapia - HCV (RESIST-HCV) (2017). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Alimentary Pharmacology & Therapeutics, 46*(7), 688–695.

Calvaruso, V., Cabibbo, G., Cacciola, I., Petta, S., Madonia, S., Bellia, A., Tinè, F., Distefano, M., Licata, A., Giannitrapani, L., Prestileo, T., Mazzola, G., Di Rosolini, M.A., Larocca, L., Bertino, G., Digiacoimo, A., Benanti, F., Guarnieri, L., Averna, A., Iacobello, C., Magro, A., Scalisi, I., Cartabellotta, F., Savalli F., Barbara, M., Davì, A., Russello, M., Scifo, G., Squadrito, G., Cammà, C., Raimondo, G., Craxi, A., Di Marco, V., Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) (2018). Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. *Gastroenterology, 155*(2), 411–421.e4.

Calvaruso, V., Cacciola, I., Licata, A., Madonia, S., Benigno, R., Petta, S., Bronte, F., Conte, E., Malizia, G., Bertino, G., Distefano, M., Montineri, A., Digiacoimo, A., Alaimo, G., Cacopardo, B., Davì, A., Guarnieri, L., Scalisi, I., Colletti, P., Cartabellotta, F., Portelli, V., Prestileo, T., Averna, A., Iacobello, C., Mondello, L., Scifo, G., Russello, M., Squadrito, G., Raimondo, G., Cammà, C., Craxi, A., Di Marco, V., Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) (2019). Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. *The American Journal of Gastroenterology, 114*(8), 1275–1282.

Caponnetto, P. (2018). Psychological and psychopathological sequelae in cardiovascular acute disease. *Mental Illness, 10*(2), 7887.

Caponnetto, P., Lai, C., Maglia, M., & Cosci, F. (2020). What clinical and health psychology tell to internists and emergency physicians about harm reduction, addiction and asthma? *Internal and Emergency Medicine, 15*(4), 571–572.

Corsaro, L.S., & Ragusa, R. (2018). Oral direct acting agent clinical trials for Hepatitis C Virus infection: an updated meta-analysis. *EC Gastroenterology and Digestive System, 5*(6), 447-455.

Di Matteo, M., Lepper, H.S., & Croghan, T.W. (2000). Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. *Archives of Internal Medicine, 160*(14), 2101–7.

Ebrahim, S. (1995). Clinical and public health perspectives and applications of health-related quality of life measurement. *Social Science and Medicine, 41*, 1383–94.

European Association for the Study of the Liver (EASL). (2018). EASL Recommendations on Treatment of Hepatitis C 2018. *Journal of Hepatology, 69*(2), 461-511.

Gold, M.R., Patrick, D.L., Torrance, G.W., Fryback, D., Hadorn, D.C., et al. (1996). Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: *Oxford University Press*.

Horsmans, Y. (2006). Interferon-induced depression in chronic hepatitis C. *The Journal of Antimicrobial Chemotherapy, 58*(4), 711–713.

Katon, W., Lin, E.H.B. & Kroenke, K. (2007). The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. *General Hospital Psychiatry, 29*(2), 147–55.

Keeffe, B. (2007). Interferon-induced depression in hepatitis C: an update. *Current Psychiatry Reports, 9*(3), 255–261.

Kuna, L., Jakab, J., Smolic, R., Wu, G. Y., & Smolic, M. (2019). HCV Extrahepatic Manifestations. *Journal of Clinical and Translational Hepatology, 7*(2), 172–182.

Lins, L., & Carvalho, F. M. (2016). SF-36 total score as a single measure of health-related quality of life: Scoping review. *SAGE open medicine, 4*, 2050312116671725.

Mandorfer, M., Payer, B.A., Scheiner, B., Breitenecker, F., Aichellburg, M.C., Grabmeier-Pfistershammer, K., Rieger, A., Trauner, M., Peck-Radosavljevic, M., Reiberger, T. (2014). Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. *Liver International, 34*(1), 69–77.

Maurihi ME (Ed.). (2011). *User’s Manual for the SF-36v2 Health Survey* (3rd ed.). QualityMetric Incorporated, Lincoln, RI.

McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mack, C., Garaud, J. J., Albrecht, J. K., & International Hepatitis Interventional Therapy Group (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology, 123*(4), 1061–1069.

Peasgood, T., Brazier, J., Mukuria, C., & Rowe, D. (2014). A conceptual comparison of well-being measures used in the UK. *Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield & York. EEPRU Research Report 026. Policy paper/document 01/09/2014*.

Pieretti, S., Di Gianuario, A., Di Giovannandrea, R., Marzoli, F., Piccaro, G., Minosi, P., & Aloisi, A. M. (2016). Gender differences in pain and its relief. *Annali dell’Istituto Superiore di Sanità, 52*(2), 184–189.

Polo, M. L., & Lauffer, N. (2017). Extrahepatic manifestations of HCV: the role of direct acting antivirals. *Expert Review of Anti-Infective Therapy, 15*(8), 737–746.

Quelas, R., & Lopes, A. (2009). Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. *Journal of Psychiatric Practice, 15*(4), 262–281.

Ragusa, R., Bertino, G., Bruno, A., Frazzetto, E., Ciccù, F., Giorgianni, G., & Lupo, L. (2018). Evaluation of health status in patients with hepatitis c treated with and without interferon. *Health and Quality of Life Outcomes, 16*(1), 17.

Scheiner, B., Schwabl, S., Steiner, S., Buesics, T., Chromy, D., Aichellburg, M. C., Grabmeier-Pfistershammer, K., Trauner, M., Peck-Radosavljevic, M., Reiberger, T., & Mandorfer, M. (2016). Interferon-free regimens improve health-related quality of life in patients with chronic hepatitis C before and during antiviral treatment with interferon-free regimens. *Journal of Clinical and Translational Hepatology, 5*(2), AS264–AS279.

Ware, J. E., Jr, Kosinski, M., Bayliss, M. S., McHorney, C. A., Rogers, W. H., & Raczek, A. (1995). Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. *Medical Care, 33*(4 Suppl), AS264–AS279.

Ware, J. E., Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care, 30*(6), 473–483.

Wei, L., & Huang, Y. H. (2019). Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert review of anti-infective therapy, *17*(5), 311–325.
WHO. (2014). Constitution of the World Health Organization. 48th ed. Basic documents of the World Health Organization. Geneva.

Younossi, Z., & Henry, L. (2015). Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. *Alimentary Pharmacology & Therapeutics, 41*(6), 497–520.

Zhou, K., Zhuang, G., Zhang, H., Liang, P., Yin, J., Kou, L., Hao, M., & You, L. (2013). Psychometrics of the Short Form 36 Health Survey version 2 (SF-36v2) and the Quality of Life Scale for Drug Addicts (QOL-DAv2.0) in Chinese mainland patients with methadone maintenance treatment. *PloS ONE,*